



Canada's source for
HIV and hepatitis C
information

La source canadienne
de renseignements sur
le VIH et l'hépatite C

From *TreatmentUpdate* 222

What's next for long-acting HIV drugs?

Two phase III trials are underway with long-acting (LA) formulations of HIV drugs. These trials will explore the safety and effectiveness of LA formulations in people new to HIV treatment (Flair) and in people who are treatment experienced (Atlas). The interim results from these two pivotal studies should be available in the latter half of 2018.

If the results from Flair and Atlas are favourable, the manufacturer of the LA drugs, Viiv Healthcare, will submit a dossier of the data to regulatory authorities. Approval should occur a year later, perhaps in the fall of 2019.

The studies we have reported on have tested LA formulations of HIV drugs as treatment. There are other studies underway in which LA cabotegravir is being tested as a form of HIV prevention. Drugs used for this purpose are called pre-exposure prophylaxis (PrEP). Results from these studies should become available in 2019.

Unresolved issues

Commenting on Latte-2, Australian researchers have said that injectable ART “might be attractive for some or many people living with HIV.” However, they also underscore that “there will inevitably be a trade-off between the convenience of not having to adhere to oral therapy and the inconvenience and discomfort associated with injectable LA ART.”

There are other issues associated with LA therapies that will affect the deployment of these medicines. For instance, the Australian researchers noted that “healthcare systems are generally not configured to facilitate regular, recurrent injections in a timely way to people who are well. Changing this will take innovation, political will and time.”

Other pharmaceutical companies are closely watching Viiv's foray into LA formulations. If Viiv's efforts are financially successful, then it is possible that one or more companies may enter the field of LA therapy for HIV.

Resource

[Long-acting therapies—safety and other issues to consider](#) - *TreatmentUpdate* 214

—Sean R. Hosein

REFERENCES:

1. Boyd MA, Cooper DA. Long-acting injectable ART: the next revolution in HIV? *Lancet*. 2017 Sep 23;390(10101):1468-1470.
2. Margolis DA, Gonzales-Garcia J, Stellbrink H-J. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomized, open-label, phase 2b, non-inferiority trial. *Lancet*. 2017 Sep 23;390(10101):1499-1510.

Produced By:



Canada's source for
HIV and hepatitis C
information

555 Richmond Street West, Suite 505, Box 1104
Toronto, Ontario M5V 3B1 Canada
Phone: 416.203.7122
Toll-free: 1.800.263.1638
Fax: 416.203.8284
www.catie.ca
Charitable registration number: 13225 8740 RR

Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: *This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.*

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at:
<http://www.catie.ca/en/treatmentupdate/treatmentupdate-222/anti-hiv-agents/what-s-next-long-acting-hiv-drugs>